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Non-alcoholic fatty liver disease comprises a broad spectrum of disease states ranging
from simple steatosis to non-alcoholic steatohepatitis. As a result of increases in the
prevalences of obesity, insulin resistance, and hyperlipidemia, the number of people with
hepatic steatosis continues to increase. Differences in susceptibility to steatohepatitis
and its progression to cirrhosis have been attributed to a complex interplay of genetic
and external factors all addressing the intracellular network. Increase in sugar or refined
carbohydrate consumption results in an increase of insulin and insulin resistance that
can lead to the accumulation of fat in the liver. Here we demonstrate how a multidis-
ciplinary approach encompassing cellular reprogramming, transcriptomics, proteomics,
metabolomics, modeling, network reconstruction, and data management can be employed
to unveil the mechanisms underlying the progression of steatosis. Proteomics revealed
reduced AKT/mTOR signaling in fibroblasts derived from steatosis patients and further
establishes that the insulin-resistant phenotype is present not only in insulin-metabolizing
central organs, e.g., the liver, but is also manifested in skin fibroblasts.Transcriptome data
enabled the generation of a regulatory network based on the transcription factor SREBF1,
linked to a metabolic network of glycerolipid, and fatty acid biosynthesis including the
downstream transcriptional targets of SREBF1 which include LIPIN1 (LPIN) and low den-
sity lipoprotein receptor. Glutathione metabolism was among the pathways enriched in
steatosis patients in comparison to healthy controls. By using a model of the glutathione
pathway we predict a significant increase in the flux through glutathione synthesis as
both gamma-glutamylcysteine synthetase and glutathione synthetase have an increased
flux. We anticipate that a larger cohort of patients and matched controls will confirm our
preliminary findings presented here.
Keywords: NAFLD, induced pluripotent stem cells, sterol biosynthesis, glutathione metabolism, lipid metabolism,
AKT/mTOR signaling, systems biology, modeling
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is on the rise in the
western population affecting one-third of adults and an increas-
ing proportion of children (de Alwis and Day, 2008; Vuppalanchi
and Chalasani, 2009). Early stages of this disease exhibit accu-
mulation of lipids in the liver leading to hepatic steatosis which
is followed by advancing levels of fibrosis and inflammation. In a
subset of these individuals the inflammatory response is accompa-
nied by hepatocyte ballooning and progression to steatohepatitis
which can lead to cirrhosis and liver cancer (Day, 2006; Petta et al.,
2009).
Hepatic steatosis is caused by the abnormal accumulation
of predominantly triglycerides (TG) in the liver. In histologi-
cal sections of liver parenchyma TG droplets are visible in the
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cytoplasm of hepatocytes. This accumulation of TG in small or
large vesicles impairs hepatic function and makes the liver more
susceptible to other injuries. It has been shown that patients with
NAFLD have a worse outcome when compared with an age and
sex-matched general population, stemming from cardiovascular
and liver related mortality (Ekstedt et al., 2006; Angulo, 2010). As
most patients with NAFLD are obese and often resistant to insulin,
steatosis can lead to significant co-morbidity or progress to non-
alcoholic steatohepatitis, thus justifying therapeutic intervention
already at the early stages. As NAFLD is highly associated with obe-
sity and diabetes, weight loss can greatly improve the health status
of these patients. However, the different susceptibility of patients
with similar body mass index (BMI) to acquire NAFLD suggests a
role for genetic factors and susceptibility genes.
The liver utilizes glycogen for energy storage and TG are usu-
ally mainly stored in adipocytes. Fatty acids originate either from
the circulation, i.e., diet, are released from adipocytes by adipocyte
TG hydrolase (ATGL) or are synthesized de novo in the liver. In
each of these metabolic pathways, multiple transcription factors
and signaling cascades (Horton et al., 2002; Li et al., 2010b) are
involved thus presenting multiple possibilities for regulation and
also deregulation of this network.
There exist several hereditary genetic disorders that demon-
strate that these networks can be deregulated in vivo. Congenital
generalized lipodystrophy, glycogen storage disease type 1a, and
citrin deficiency all cause severe hepatic steatosis even in the
absence of obesity or insulin resistance. Several mutations and
genetic defects are known to influence TG accumulation in the
liver, like mutations of ATGL which prevent mobilization of TG
from the hepatocytes or mutations in apolipoprotein B which
impair TG secretion to the bloodstream (Hooper et al., 2011).
However, single gene mutations are only rarely responsible for
NAFLD with the majority of cases caused by changes in the quan-
tity and composition of food consumed in the western hemisphere.
The Dallas Heart Study, which included 2000 individuals of multi
ethnic origin, has shown that hepatic steatosis is rare in lean indi-
viduals with a BMI< 25 kg/m2 whereas it is highly prevalent in
obese participants presenting a BMI> 45 kg/m2 (Browning et al.,
2004).
In summary, hepatic steatosis is clearly correlated to food
intake and insulin resistance. However, even in the severely obese,
large differences in the extent of steatosis can be observed. As
steatosis stands at the start of the road to non-alcoholic steato-
hepatitis (NASH) and hepatocellular carcinoma (HCC), finding
genetic determinants of susceptibility to NAFLD might help in
the prevention of NASH and HCC.
Studying NAFLD in human patients is limited by the need
for liver biopsies to determine the stage of NAFLD and by the
strong influence of the individual environment of the patient with
respect to food intake and exercise. Nevertheless some genome
wide association studies have recently been performed and iden-
tified genetic variants that have distinct effect on metabolic traits
(Speliotes et al., 2011). Animal models have shed light on a causal
relationship between insulin resistance and hepatic steatosis but
so far failed in elucidating useful genetic markers to determine
the susceptibility of individuals to develop NAFLD (Voshol et al.,
2003; den Boer et al., 2004).
Hepatocytes generated from induced Pluripotent Stem (iPS)
cells can thus present a model system in which the response of naïve
hepatocytes with the patient’s genome to experimental stimuli can
be tested and analyzed. These unique features of iPS cell-derived
hepatocytes could help in elucidating the genetic networks that are
responsible for the different reaction of the patients hepatocytes
to the environmental stimulus presented to them by the patient’s
lifestyle.
In this manuscript we illustrate how a multi-disciplined systems
biology approach can be used to study the etiology of steatosis.
The scheme presented in Figure 1 shows the interactions between
wet-labs (cell biology and biochemistry) and in silico analysis
which is made up of data integration, pathway reconstruction,
and modeling. A description of the consortium can be found at
http://www.erasysbio.net/index.php?index=264.
MATERIALS AND METHODS
PATIENT RECRUITMENT AND SAMPLE COLLECTION
Starting in 2009, patients with morbid obesity were offered to par-
ticipate in the Multidisciplinary Obesity Research (MORE) project
at the Medical University of Graz, Austria. This study aims to take
an interdisciplinary approach in research on obesity and related
diseases like insulin resistance, liver steatosis and metabolic syn-
drome and includes the Institutes of Gastroenterology, Pathology,
Surgery and Experimental Hepatology at the University Hospi-
tal of Graz. Patients with morbid obesity admitted into hospital
for treatment by bariatric surgery (gastric banding, gastric bypass,
sleeve gastrectomy) were invited to participate in the study and to
sign the informed consent. In addition to obese patients we also
included three healthy individuals in the study to obtain control
dermal fibroblasts. If patients were admitted for bariatric surgery,
samples of blood, skin and a liver biopsy were taken during the
operation. The skin samples were immediately transported to the
Institute of Pathology and fibroblast cultures were initiated. The
liver biopsy was divided into one part for fixation and histology
and a second part for liquid nitrogen storage while the blood
sample was separated into mononuclear cells and plasma. Subse-
quently the disease phenotype characterization comprised detailed
analysis of glucose (e.g., type 2 diabetes, insulin resistance) and
lipid metabolism, hypertension, atherosclerosis, and histopatho-
logical evaluation of the liver biopsy. In addition, HOMA IR
(homeostatic model assessment insulin resistance) was calculated
for patients. The average normal-weight individual has an insulin
resistance of 1, while for obese patients recruited for the study the
HOMA IR index is within the range from 2.82 to 4.86, indicating
the insulin resistance phenotype. Moreover, other diseases had to
be excluded, and a detailed evaluation of the lifestyle (nutrition,
physical activity and consumption of alcohol or drugs) was per-
formed from the structured questionnaires and, where applicable,
biomarkers and physical measurements.
DERIVATION OF DERMAL FIBROBLAST CELLS FROM PATIENTS
Primary fibroblasts were derived by standard tissue culture prac-
tice. In brief, the skin surface was sterilized with ethanol and
subcutaneous fat was removed. The sample was divided into small
pieces (2 mm× 2 mm) and each of these pieces was minced in
a culture dish, supplemented with 1 mL of DMEM, 10% FCS
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FIGURE 1 | Interdependencies between the wet-lab data and in silico
data to decipher the biology of NAFLD. The complex systems biology of
NAFLD is explored by a multidisciplinary consortium of clinical and research
groups having profound expertise in the fields of stem cells, pathology of
chronic liver and metabolic disorders, development of a Biobank to support
drug discovery, high-throughput sequencing, functional genomics,
bioinformatics and systems biology. ODE-modeling refers to Ordinary
Differential Equation-based modeling.
with antibiotics, and covered with a sterile coverslip. After approx-
imately 2 weeks skin fibroblasts started to grow out from the
skin pieces and after approximately 4 weeks the fibroblasts were
harvested and expanded.
Primary fibroblasts from two patients with steatosis (H0007,
H0008) and a non-obese control (H0002) were established.
PROTEIN LYSATE PREPARATION
After washing with PBS two times cells were directly lysed in M-
PER buffer (Pierce) with EDTA free complete inhibitors (Roche)
and phosphostop (Roche). Lysates were immediately frozen at
−80˚C. Further samples were allowed to thaw on ice and incubated
on a rotating shaker at 4˚C for 20 min. To clear protein samples,
lysates were centrifuged at maximum speed for 30 min at 4˚C. The
protein supernatant was collected and protein concentration was
estimated using a micro BCA method (Smith et al., 1985).
REVERSE PHASE PROTEIN ARRAY
The method used in this study has been described previously
(Loebke et al., 2007). For each sample four replicate spots were
printed using the 2470 Arrayer (Aushon Biosystems, Billerica,
USA). Slides not used immediately were kept a −20˚C and rehy-
drated in PBS-Tween (0.05%). Blocking was carried out using
Odyssey Blocking buffer (LI-COR, Lincoln, USA) diluted to 1:1
with PBS-Tween (0.05%) containing NaF and NaVO3 for 1h at
room temperature. Next, slides were incubated with pre-validated
antibodies (Table 1) at 1:300 dilutions in blocking buffer overnight
at 4˚C. Primary antibody detection was carried out with Alexa-680
labeled goat-anti-rabbit or goat-anti-mouse secondary antibodies
Table 1 | List of the pre-validated antibodies used in reverse phase
protein array (RPPA).
Target Phosphosite Antibody ID Company
ERK1/2 T202Y204 4370 Cell Signaling Technology
PRAS40 T246 2997 Cell Signaling Technology
AKT S473 4058 Cell Signaling Technology
PEPCK sc-32879 Santa Cruz Biotechnology
4EBP1 NB200157 Novus Biologicals
TSC1 4906 Cell Signaling Technology
TSC2 3990 Cell Signaling Technology
CD36 AF2519 R&D Systems
and visualized using an Odyssey scanner (LI-COR, Lincoln, USA).
Array images were analyzed and quantified using GenePix Pro 5.0
software (Molecular Devices, Ismaning, Germany). For on-slide
protein quantification the total protein content of single spots was
determined according to the FAST Green-FCF assay (Loebke et al.,
2007).
DATA ANALYSIS OF REVERSE PHASE PROTEIN ARRAYS
Data analysis was performed using the software tool RPPanalyzer
(Mannsperger et al., 2010) implemented in the statistical environ-
ment R. Arrays with signal intensities not significantly above blank
readings as well as arrays without a linear correlation between
signal intensity and protein concentration were not analyzed. Sig-
nificance was calculated applying two-sample t-tests. Raw data was
www.frontiersin.org September 2012 | Volume 3 | Article 339 | 3
Jozefczuk et al. iPSCs-based model of steatosis
normalized for total protein content using FCF data as described
before (Loebke et al., 2007). To obtain significantly regulated pro-
teins, t-test statistics were applied. Three biological replicates and
five technical replicates were tested and p-value was adjusted for
multiple testing.
TRANSCRIPTOME ANALYSIS OF PATIENT SPECIFIC FIBROBLASTS AND
CONTROL
Gene expression analysis was performed using the Illumina
HumanRef-8 v3 BeadChip. The bead-level data generated by the
image scanner software were summarized and saved without back-
ground correction and normalization in the Illumina BeadStudio.
Bead-summary data was analyzed via R/Bioconductor (Gentle-
man et al., 2004) and the lumi package (Du et al., 2008) starting
with background subtraction, variance-stabilizing transforma-
tion and quantile normalization. Fibroblasts from two steatotic
patients (H0007, H0008) were compared to control fibroblasts
from a non-steatotic person (H0002). For each patient two repli-
cates were hybridized. Differential expression was tested using
Welch’s test and the moderated t-test from the limma (Smyth,
2004) package test in parallel. The list of significantly expressed
genes was based on limmap, which represents the p-value from
moderated t-test from limma-Package (limmap< 0.05) and the
p-value from Welch’s test (t2p< 0.05). The Bioconductor package
q-value (Storey, 2002) was employed to control the false discov-
ery rate. Genes were considered differentially expressed when the
Illumina detection p-value (judging significance of discrimina-
tion from the microarray image background) of at least one of
the control or treatment group and the false discovery rate were
usually 0.05.
Microarray data analysis was then performed on data grouped
into the following combinations: steatosis patient H0007 vs. con-
trol, steatosis patient H0008 vs. control and steatosis patients
H0007 and H0008 vs. control in order to identify the major mark-
ers and molecular read-outs as well as annotation of the functional
networks that interconnect these markers. All original gene array
files are available from the Gene Expression Omnibus (GEO)
database1 accession number GSE37689.
DISCOVERY OF PATHWAYS AND FUNCTIONAL MODULES THROUGH
NETWORK ANALYSIS FOR THE DEVELOPMENT OF COMPUTATIONAL
MODELS
Gene-set enrichment and over-representation analysis (ORA) was
achieved utilizing the unique pathway database integration sys-
tem ConsensusPathDB (Kamburov et al., 2009, 2011b) which is
designed with a focus on human pathway and interaction data
and integrates the content of most important pathway databases
such as Reactome (Matthews et al., 2009; Croft et al., 2011), KEGG
(Kanehisa et al., 2010), IntAct (Kerrien et al., 2007), DIP (Salwin-
ski et al., 2004) as well as manually curated data resulting from
experimental investigation or interaction data available in com-
mon pathway and systems biology file formats, such as SBML
(Hucka et al., 2003), BioPAX (Demir et al., 2010), or PSI-MI
(Hermjakob et al., 2004). The current content of the integra-
tion tool comprises more than 51,000 physical entities with more
1http://www.ncbi.nlm.nih.gov/geo/
than 1,69,000 functional interactions. Pathway analysis with a
daughter tool of ConsensusPathDB, IMPaLA (Kamburov et al.,
2011a) has been used to identify pathways related to signaling and
metabolism. In addition to over-represented pathways, also near-
est neighborhood-based entity sets (NESTs) can be identified with
ConsensusPathDB. NESTs are centered at a specific entity (gene,
metabolite, etc.) and contain all direct interactions and interaction
partners. Thus, NESTs can be viewed as unbiased (non-annotated)
functional modules derived from the integrated network that can
be used as gene sets for gene enrichment analyses as an alterna-
tive to curated pathways. NESTs can further be restricted with
statistical graph-theoretical arguments, for example minimal con-
nectivity, minimal degree, etc. Identified pathways and functional
modules have been integrated in a prototype model related to
disease development of steatosis and steatohepatitis.
MODELING GLUTATHIONE SYNTHESIS AND METABOLISM PATHWAYS
For this work an updated version of the glutathione model pre-
viously published was used (Reed et al., 2008; Geenen et al.,
2012). The model is available for simulation at all three JWS
Online (Olivier and Snoep, 2004) servers (e.g., http://jjj.mib.ac.uk/
webMathematica/Examples/run.jsp?modelName=geenen). The
modified model consists of the methionine cycle, glutathione
synthesis and detoxification, ophthalmic acid synthesis, and the
gamma-glutamyl cycle. We are more confident in the ability of this
model to make quantitatively accurate predictions as this model
was fitting on more experimental data (than the previous model)
and is partially validated (Geenen et al., manuscript in prepara-
tion). However we have not validated the model for predicting the
effect in changes in V max and therefore the predictions made here
will offer limited certainty.
This model represents the control data set discussed in this
study. The difference in expression between control (H0002) and
steatosis (H0007, H0008) was first calculated and then used to cal-
culate the V max for H0007 and H0008. In order to take account of
the differences of expression within the repeats, the V max of all the
repeats was calculated. This was then inputted into the model as a
range of V max. The range of V max inputted into the model for the
control model (H0002), patient H0007, and H0008 are presented
in Table A1 in Appendix.
Similarly, a range of V maxs was also incorporated in the control
model based on the range of expression data of the control patient.
Three models were then analyzed: the control (H0002) model,
H0007, and H0008. In order to calculate the fluxes/concentrations
of the model, the model selected a V max value for each enzyme
within the new calculated range and the steady state was calcu-
lated. This was repeated 5,00,000 times using Condor-COPASI2
(Hoops et al., 2006). This resulted in 5,00,000 different steady
states due to the different combinations of V max values randomly
chosen by COPASI. The average and standard deviation (SD) of
flux/concentration was calculated from this data.
RESULTS
PATHOMORPHOLOGICAL ASSESSMENT OF PATIENT’S PHENOTYPE
Pathomorphological assessment of the histology of the liver biop-
sies (Figure 2) allowed to select three patients with high grade
2http://www.comp-sys-bio.org/condor-copasi
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FIGURE 2 | Hematoxylin-Eosin stained sections of liver biopsies from the four patients enrolled in the study (top: control (left), steatosis (H0008,
right); bottom: steatosis (H0007, left), sinusoidal dilatation and inflammation (right).
steatosis (>30% steatosis, BMI 44± 3) and three patients with
low grade steatosis (0–10% steatosis, BMI 42± 7) with similar
BMI. These samples are supplemented by three control samples
from healthy individuals. The number of samples is still small so
sample acquisition is ongoing. The scheme in Figure 3 depicts the
overall strategy for accomplishing our aims.
iPS CELL-BASED DERIVATION OF AN IN VITRO DISEASE MODEL OF
STEATOSIS
Retroviruses encoding the reprogramming factors, OCT4, SOX2,
KLF4, and c-MYC were transduced into fibroblasts cells from
patient with steatosis (H0008) and control (H0002) using well
established protocols (Takahashi et al., 2007; Wolfrum et al., 2010).
These iPS lines express the embryonic stem cell specific mark-
ers, NANOG, SOX2, OCT4, SSEA4, TRA-1-60, and TRA-1-81
(Figure 4).
COMPARATIVE TRANSCRIPTIONAL ANALYSIS OF DERMAL
FIBROBLASTS DERIVED FROM STEATOTIC PATIENTS (H0007 AND
H0008) AND HEALTHY INDIVIDUAL SERVING AS CONTROL (H0002).
The transcriptomes of dermal fibroblasts derived from two
patients with steatosis [60 year, male BMI 45.7 (H0008) and
33 year, female, BMI 51.3 (H0007)] and control fibroblasts
[19 year, female, BMI 21 (H0002)] were analyzed. The cluster-
ing of the respective transcriptomes is shown in Figure 5A, the
correlation co-efficient ranged from 0.92 to 0.96.
First we considered all genes expressed (detection p-
value< 0.01) in steatotic (H0007, H0008) and control (H0002)
fibroblasts. TheVenn diagram in Figure 5B illustrates that there are
208 genes exclusively expressed in fibroblasts from patients with
steatosis. Several examples of overlapping genes (including seven
genes involved in metabolism of lipids and lipoproteins, high-
lighted in bold) are presented in Figure 5C. The complete list of
208 overlapping genes is provided in Table 2, amongst this list are
genes (represented as CORFs, FLJs, and LOCs) of unknown func-
tion and therefore considered as novel steatosis-associated genes.
TARGET AND PATHWAY IDENTIFICATION, ANNOTATION AND
COMPUTATIONAL MODELING
In order to assess whether the differentially expressed genes
in steatosis patients (H0007 and H0008) compared to control
FIGURE 3 | Workflow of patients recruitment, sample collection, and
downstream analyses. The computational model of NAFLD will be
generated based on hepatocyte-like cells challenged with “environmental”
conditions typical for NAFLD. Data obtained from in vitro studies will be
compared with data from liver biopsies and further validated in vitro on
hepatocyte-like cells.
(H0002) are enriched with respect to specific pathways, ORA
was carried out with ConsensusPathDB. Using the hyperge-
ometric test statistic of ConsensusPathDB on genes that are
differentially expressed in the patients we were able to assign
each pathway a p-value reflecting the occurrence of candidate
genes for steatosis. ORA revealed top ranked pathways related
to DNA replication (patient H0007, p-value= 3.22e−8; patient
H0008, p-value= 2.95e−6) and cell cycle (patient H0007, p-
value= 1.05e−6; patient H0008, p-value= 3.22e−8). Further-
more, ORA suggests that members of the NEST set related to
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FIGURE 4 |The patient-specific fibroblasts were transduced with
the ES cell specific transcription factors OCT4, SOX2, KLF4, and
c-MYC. Then grown on MEFs in ES cell culture medium. After 3 weeks
flat ES-like colonies were observed and picked mechanically. (A) Phase
contrast images of dermal fibroblasts derived from skin biopsies of
steatosis patient (H0008) and control individual (H0002). (B) Phase
contrast images of iPS cells derived from dermal fibroblasts and
staining of alkaline phosphatase which is a marker associated with
undifferentiated pluripotent stem cells. (C) Characterization of iPS cells.
iPS cells express the crucial pluripotency-associated transcription
factors NANOG, OCT4, SOX2 as well as cell surface markers TRA-1-81,
TRA-1-60, and SSEA4. Scale bar=100µm.
glutathione metabolism (patient H0007, p-value= 0.0127; patient
H0008, p-value= 5.61e−5) show jointly significant increase in
transcription levels in steatosis patients. The NEST analysis
is based on the genes glutathione S-transferase A4 (GSTA4),
glutathione S-transferase theta-1 (GSTT1), and glutathione S-
transferase mu 1 and 2 (GSTM1, GSTM1), which were identified
as parts of the glutathione metabolism pathway, and the analysis
identified a NEST gene-set that is centered around cytochrome
CYP4F22 (p-value= 8.67e−11, Figure 6). The gene CYP4F22,
encodes a member of the cytochrome P450 superfamily of
enzymes. Cytochrome P450 proteins are mono-oxygenases which
catalyze many reactions involved in drug metabolism and synthesis
of cholesterol, steroids, and lipids. The gene GSTA4, which is found
to be up-regulated in the fibroblasts of the two steatosis patients,
catalyzes the reaction of reduced glutathione to 4-hydroxynonenal,
a product which is considered as a marker for oxidative damage
in tissue. Furthermore, GSTM1 and GSTM2 that are found to be
up-regulated in the fibroblasts of the two steatosis patients are
known to be induced by oxidative stress. Moreover, glutathione
peroxidase 4 (GPX4) is up-regulated in the steatosis patients
and catalyzes the formation of the oxidized form of glutathione
(glutathione disulfide, GSSG) from glutathione (GSH). GPX4 is
the only antioxidant enzyme known to directly reduce phospho-
lipid hydroperoxides within membranes and lipoproteins, acting
in conjunction with alpha-tocopherol to inhibit lipid peroxidation
(Sneddon et al., 2003). In contrast to GSTM2, GSTM1, GSTA4, and
GPX4 which are up-regulated in the steatosis patients, GSTT1 is
found to be down-regulated. GSTT1 is known to be transcription-
ally regulated by C/EBP-alpha which is considered to be critical
for glucose and lipid homeostasis in adult mice (Inoue et al.,
2004).
FREE FATTY ACIDS INDUCED DE NOVO LIPID SYNTHESIS BY
ACTIVATION OF NUCLEAR RECEPTORS SREBF1 AND PPARG
Figure 11 depicts a minimal model of steatosis based on the
patients transcriptome and associated pathways. The genes LPIN
and LDLR which encode lipin and low density lipoprotein recep-
tor (LDLR), respectively, are downstream targets of SREBF1 (Fajas
et al., 1999) and are up-regulated in both steatosis patients. SREBF1
encodes a transcription factor that binds to the sterol regulatory
element-1 (SRE1),which is a decamer flanking,e.g., the LDL recep-
tor gene (LDLR) and other genes involved in sterol biosynthesis. In
addition to the transcriptional activation of LPIN and LDLR, Fajas
et al. reported that SREBF1 regulates the expression of PPARG
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FIGURE 5 | Comparative transcriptional analysis of dermal fibroblasts
from steatotic patients (H0007 and H0008) and healthy individual
(H0002). (A) The clustering of respective transcriptomes. (B) The Venn
diagram illustrating the distinct and overlapping genes. (C) List of 20 genes
expressed in both patient-derived fibroblasts. Seven genes involved in
metabolism of lipids and lipoproteins (highlighted in bold).
during adipocytes differentiation. Ishimoto et al. (2009) demon-
strated that the transcription of LPIN1 is mediated by SREBF1 and
nuclear factor Y (NF-Y) and has been identified to be regulated by
cellular sterols, which play an important role in lipid metabolism.
LPIN1 is involved in glycerolipid biosynthesis and catalyzes the
synthesis of diacylglycerol (DAG).
In addition, SREBF1 regulates the expression of the gene
PPARG that encodes the peroxisome proliferator-activated recep-
tor gamma which is a regulator of adipocyte differentiation.
PPARG has been implicated in the pathology of numerous diseases
including obesity, diabetes, atherosclerosis, and cancer. PPARs can
form heterodimers with retinoid X receptors (RXRs) regulating
the transcription of genes encoding lipid droplet (LD) proteins
such as PLIN1, PLIN2, PLIN3, PLIN5, FSP27, and HIG2, known
to be expressed in steatotic liver. LD proteins play a role in the
pathophysiology of fatty liver disease where hepatocytes enriched
with LD proteins contain vast amounts of lipids.
TARGETED PROTEOMICS USING REVERSE PHASE PROTEIN ARRAYS
Reverse phase protein arrays (RPPA) were used to analyze protein
extracts derived from skin fibroblast cell lines obtained from two
steatosis patients (H0007, H0008) and from a healthy lean con-
trol (H0002). In detail, the expression level of 109 proteins and
phosphoproteins was quantified and several target proteins as well
as phosphoproteins were identified as differentially regulated. For
example, phosphorylation levels of major signaling proteins such
as AKT, PRAS40, p70S6K (T389), ERK1/2 were strongly and signif-
icantly reduced in both patient-derived fibroblast cell lines whereas
expression and phosphorylation of insulin receptor beta (IRβ) and
its key adaptor protein IRS1 were comparable in control cells.
In animal models of diabetes as well as in human type 2
diabetes, a down-regulation of AKT/mTOR signaling indicates
impaired insulin signaling (Sesti et al., 2001). Likewise, reduced
p70S6K1 (T389) phosphorylation in response to insulin was pre-
viously reported as a characteristic feature of adipocytes obtained
from patients with type 2 diabetes (Ost et al., 2010). This suggests
that at the level of AKT/mTOR signaling, fibroblast cells obtained
from steatosis patients phenocopy features of insulin resistance.
However, while animal models of insulin resistance suggest
increased ERK signaling as well as an increased phosphorylation
of IRS1 on its key activation site S632 (corresponding to S636 in
human IRS1; Bouzakri et al., 2003), a significant down-regulation
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Table 2 | List of 208 genes expressed in common between fibroblasts derived from two steatotic patients.
GENES EXPRESSED IN COMMON BETWEEN FIBROBLASTS FROM STEATOTIC PATIENTS (H0007 and H0008)
ABCD1 C9ORF111 DLX1 HCAP-H2 MGAT2 PI16 SEMA3B TRAPPC6A
ACSS1 C9ORF150 DMWD HFE MGC13024 PIGZ SEMA5A TREX1
AKAP12 C9ORF16 DOCK6 HIST1H4H MMP11 PITX1 SGK3 TRIM16L
ALKBH1 CART1 DSCAM HOXA6 MORC4 PLAGL1 SLC12A8 TRIM47
AMPH CASP9 DYRK1B HOXC10 MRPL10 POMZP3 SLC1A3 TRIM9
ANK3 CCNL2 DYRK2 HTATIP MTG1 PPP2R3B SLC25A20 TTLL1
AP3M1 CCNT2 EDG4 IL17RB MTHFR PRICKLE1 SLC26A6 UBOX5
APOD CD9 EFTUD1 IRX1 MX2 PRR3 SLC35C2 UNC13B
ARHGEF10L CDKN2C EPC1 KBTBD3 MYOM2 PSMF1 SLC7A7 USH1G
ASCC3 CDO1 F25965 KIAA1967 NBPF1 PSRC2 SLC9A9 UTP15
ATP5G2 CEP250 FAM102A KIFC2 NFKBIZ PTGDS SLITRK4 VIT
BCR CFD FBXL7 KLF8 NGDN PTP4A3 SNURF VPS13C
BRWD2 CLYBL FBXO3 LARP2 NME2 PTPN9 SNX1 VPS8
BTN3A3 CMYA5 FLJ13639 LGP2 NOL1 PTPRE STAP2 VWCE
BUB3 CPT1B FLJ20422 LMAN1 NTN4 PTX3 SYVN1 WDR33
BVES CPZ FLJ22167 LOC158160 OR11L1 RAB23 TACSTD2 WDR81
C11ORF11 CSPP1 FLJ40142 LOC652968 OSR2 RASIP1 TAPBP WNT2
C14ORF28 CTSH FLT3LG LOC653626 PARP16 RBBP9 TBC1D10A ZCRB1
C14ORF37 CXORF56 G3BP2 LRIG3 PARP6 RBMS3 TGIF2 ZFYVE27
C16ORF28 CYFIP1 GALNT12 LSM14B PCDHB2 RDH13 THBS3 ZNF266
C1ORF115 CYP26B1 GALNTL1 MAFG PCDHGB6 REEP6 TLE1 ZNF42
C20ORF161 DACT1 GALNTL2 MAPK14 PCNXL2 RGN TLR4 ZNF521
C21ORF56 DAPK2 GEM MBP PDCD8 RNF8 TM4SF1 ZNF580
C21ORF63 DCTN1 GGPS1 MCPH1 PFKL RRN3 TM7SF2 ZNF586
C5ORF4 DENND2A GPR37 MDK PHACS SC4MOL TP53INP1 ZNF589
C6ORF48 DHRS10 GUSBL2 MFI2 PHF11 SCARB1 TRAF3IP2 ZNFN1A2
of phosphorylated ERK was observed for both patient-derived
fibroblast cell lines. Patient H0008 cells revealed also decreased
levels of IRS S636 (Figure 7). Thus, at the level of ERK signaling,
notable differences exist between features characteristic for ani-
mal models of diabetes and fibroblast cells derived from steatosis
patients.
The fatty acid translocase CD36 was up-regulated at the pro-
tein level in both steatosis patient samples although only signif-
icantly in cells derived from patient H0008, thus suggesting an
increased uptake of lipids in steatosis patients. An up-regulation of
CD36 in liver cells has also been associated with insulin resistance
(Miquilena-Colina et al., 2011). Furthermore, fibroblasts from
patient H0008 showed elevated expression of phosphoenolpyru-
vate carboxykinase 2 (PEPCK), a major enzyme of gluconeogene-
sis. Up-regulation of PEPCK and CD36 was previously reported to
occur after inhibition of mTOR signaling by rapamycin (Houde
et al., 2010) which is mimicked by the up-regulation of mTOR
inhibitor proteins TSC1 and TSC2 in fibroblast cells derived
from patient H0008. In conclusion, our data indicate impaired
AKT/mTOR signaling exists in fibroblast cells derived from steato-
sis patients and that numerous features typical for diabetes type 2
were also observed in steatosis patients. Thus, molecular features
of insulin resistance are present in skin fibroblasts of steatosis
patients.
However, the question how other signaling pathways such
as those mediated by ERK and PKCα contribute to the
insulin-resistant phenotype and how this impacts on phosphory-
lation of IRS1 as key regulator of insulin responsiveness remains to
be elucidated. Targeted proteomics carried out on larger numbers
of human steatosis samples will certainly provide a meaningful
contribution to the ongoing debate on molecular mechanisms that
are causative for insulin resistance and thus also identify points
for clinical intervention contributing to personalized therapies of
steatosis patients.
MODELING THE GLUTATHIONE SYNTHESIS PATHWAYS IN DERMAL
FIBROBLASTS FROM STEATOSIS AND CONTROL
Preliminary investigation involved analysis of the transcriptome
profiles, Gene Ontology (GO) ORA and KEGG pathway analy-
sis, which selected for the implementation of a kinetic model for
glutathione synthesis and metabolism (updated from the pre-
vious model published by Geenen et al., 2012). In H0007 vs.
control (H0002), enrichment of filtered gene lists was observed
in the following pathways: glutathione metabolism, metabo-
lism of xenobiotics by cytochrome P450, and specifically drug
metabolism by cytochrome P450. Similarly, in H0008 vs. con-
trol (H0002), enrichment of filtered genes was observed in the
aforementioned pathways but also the TGF-β signaling pathway.
Combining data sets from both patients selected for the glu-
tathione synthesis and metabolism pathways to be of interest,
forming the basis for the construction/implementation of a kinetic
model.
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FIGURE 6 | A functional interaction sub-network visualized by
ConsensusPathDB’s network visualization framework. This sub-network
defines the neighborhood-based entity set of genes playing a role in
glutathione metabolism centered by cytochrome P450. The sub-network
consists of 25 biochemical interactions (green circles), compounds, and
metabolites are illustrated as light brown rectangles. Beyond the proteins that
are visualized as light blue rectangles are the enzyme encoding genes GSTT1,
GSTM2, GSTM1, and GPX4 which are differentially regulated in patients
H0007 and H0008 in comparison to the control, H0002. Ratios of GPX4,
GSTM2, GSTT1, GSTM1, and GSTA4 are also highlighted in red
(up-regulation) or green (down-regulation). Four interactions from the KEGG
Database are illustrated in this figure.
GLUTATHIONE PATHWAY
Our hypothesis was that the flux through the glutathione path-
way of the steatosis patients would be higher due to the steatosis
grade (as determined from histology). We acknowledge clinical
projects are often challenged with unbiased sample numbers, so
we compared each patient data with control independently.
The flux through glutathione synthetase (final step in glu-
tathione synthesis) was observed to be higher in H0008 than
control. The flux through glutathione synthetase was not signif-
icantly different between H0007 and control. The flux through
glutamylcysteine synthetase (second to last step in glutathione
synthesis) was higher in H0008 than in the control. The aver-
age concentration of glutathione was higher in H0008 compared
to control but lower in H0007 than in control (Figure 8). We then
used the model to investigate the reason for this change in glu-
tathione level, i.e., explain the higher glutathione concentration
by higher flux through glutathione synthesis pathway. To under-
stand the decrease in glutathione concentration (even though flux
through glutathione synthesis seems to be unchanged) we inves-
tigated the rate of degradation of glutathione. The increase in
expression of glutathione peroxidase led to an increase in the flux
through reaction in the model compared to control, which may be
a possible explanation for this decrease.
CORRELATION BETWEEN CHANGE IN FLUX AND CHANGE IN Vmax
One of the assumptions of analyzing expression data was that
a change in mRNA expression is correlated to changes in the
pathway flux/behavior. The advantage of combining the mRNA
expression data to the kinetic model would be to investigate how
a change in expression might affect flux (we now assume that a
change in mRNA is equal to a change in V max). To see whether
the model predicts different effects on the pathway flux/behavior
compared to using the mRNA data alone, we investigated whether
there is a correlation between change in the V max and change
in the flux through the pathway. To test this we investigated two
enzymes/reactions which had the largest change in expression; 5-
oxoprolinase and DNA (cytosine-5-)-methyltransferase 1 and then
one with smaller changes of expression; glutathione synthetase.
The expression of 5-oxoprolinase was 1.86 times higher in
H0008 than control (H0002). The increase in flux though 5-
oxoprolinase (v27 in model; Geenen et al., 2012; corresponding
enzyme/reaction) was 1.64 (Figure 9A) implying there is a good
correlation between flux and change in V max. Figure 9A shows that
an increase of flux of 1.86 times lies within the error bars of the
flux predicted for H0008. DNA (cytosine-5-)-methyltransferase 1
was 2.33 times lower in H0007 than in control. The decrease of
flux through v11 was 1.79 times lower implying when compared
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FIGURE 7 | Heat map presenting differentially expressed proteins. Proteomic profiling was carried out for samples provided by the consortium such as
fibroblasts from two patients with steatosis (H0007, H0008) and a non-obese control (H0002).
to 5-oxoprolinase, here the correlation between flux and change
in V max was not as good (Figure 9B). The glutathione synthetase
expression data showed that H0008 had 1.26 times higher expres-
sion, and H0007 had 1.2 times lower expression than control. The
flux showed that H0008 had a 1.05 times higher flux and H0007
had a 1.01 times higher flux (Figure 9C). This led to a poor cor-
relation between flux and V max. The insertion of the expression
data into a kinetic model of the glutathione pathway allowed us
to predict what the effect of expression changes might be on path-
way flux. The results suggest that H0008 could have a significant
increase in the flux through glutathione synthesis as both gamma-
glutamylcysteine synthetase and glutathione synthetase have an
increased flux through them. A significant change in flux through
glutathione synthesis of H0007 was not observed. Through this
model, we have shown that a good correlation between change in
flux and change in V max may not always be the case. This sug-
gests adopting systems-based approaches (modeling approaches)
have an advantage over analyzing mRNA expression data alone to
synthesize information.
DATA INTEGRATION AND MANAGEMENT
The principle of the livSYSiPS data management platform is
to provide a user-friendly interface without superficial elements
catering for easy access and exploitation of project data follow-
ing the model of popular search engines in the World Wide
Web. Requirements for the data management system of project
livSYSiPS were analyzed taking into account dedicated use cases.
Data formats generated in the experiments were assessed to find
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FIGURE 8 | Glutathione synthesis pathways in dermal fibroblasts from
patients with steatosis and control. (A) The average flux through
glutathione synthetase (the final step in glutathione synthesis). (B) The
average flux through glutamylcysteine synthetase (the second to last step in
glutathione synthesis). (C) The average concentration of glutathione. Error
bars are SD.
appropriate metadata models and standard data formats facilitat-
ing good representations of experiments in their systems biologic
environment.
The Data Integration Platform for Systems Biology Co-
operations (DIPSBC; Dreher et al., 2012) which was developed
at the Max Planck Institute for Molecular Genetics in Berlin
was adapted for the livSYSiPS project at the Charité, Berlin. The
DIPSBC is based on wiki technique and the solr search server
from the Apache open source project. Wiki and solr platform
are brought together via a dedicated solrSearch plugin. The user
interface – emphasizing the central search box – is intended to
provide clear and easy-to-use access to project data and mani-
fold representations and visualizations of it (Figure 10). In addi-
tion to the search engine interface a navigation bar on the front
page links directly to the most prominent categories of data. The
DIPSBC uses metadata defined via XML descriptions of data. The
use of XML as metadata promotes the use of standard formats
which are crucial for data sharing. Schema definitions for for-
mats from the Minimum Information for Biological and Biomed-
ical Investigations (MIBBI; Taylor et al., 2008) recommendations
have been implemented, e.g., for Minimum Information About a
Microarray Experiments (MIAME; Brazma et al., 2001). Systems
biology resources, e.g., BioModels (Li et al., 2010a), Kyoto Ency-
clopedia of genes and genomes (KEGG; Kanehisa et al., 2010),
and the ConsensusPathDB (Kamburov et al., 2011b) have been
integrated. In a typical application, KEGG pathways enriched
in the experimental data can be explored. The system provides
statistical parameters for the dedicated tests and a prediction
for activation or inhibition via the Bioconductor SPIA pack-
age (Tarca et al., 2009). Independent of the significance of the
pathway as whole, differentially expressed genes can be visual-
ized in the KEGG pathway chart. The repository allows direct
access to raw data and processed data. The livSYSiPS data man-
agement is integrated into the system ERASysBio+ SEEK which
provides a supervising data management platform for multiple
transnational systems biology research projects. The site pro-
tected livSYSiPS webpage can be found at the following link:
http://sheldon.charite.de/foswiki/bin/view/LIVSYSIPS/WebHome
The site will be available to the general public at the end of the
project. For intra-project communication a user forum has been
set up which is used for, e.g., exchanging minutes of meetings,
slides of talks, etc. and most importantly enables web discussions
about project related issues.
The following datasets have so far been incorporated into the
database:
I. Microarray-based transcriptome data pertaining to the differ-
entiation of healthy human embryonic stem cells and induced
pluripotent stem cells into hepatocyte-like cells (Jozefczuk
et al., 2011).
II. Transcriptome data of fibroblasts derived from patients with
steatosis (H0007, H0008) and control (H0002).
III. Microarray-based transcriptome data of human hepatocellu-
lar xenograft models (Kashofer et al., 2009).
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FIGURE 9 | Correlation between change in flux and change in
V max. (A) The average flux through oxoprolinase (v27) for the patient
with steatosis (H0008) and control. (B) The average flux through
DNA (cytosine-5-)-methyltransferase (v11) for the patient with
steatosis (H0007) and control. (C) The average flux through
glutathione synthetase. The red bar is the predicted value of flux
based on mRNA expression. Error bars on model predicted changes
in flux are SD.
IV. Reverse Phase Protein Array data.
V. Systems biology models from the BioModels database.
VI. Consensus pathway data integrating multiple pathway data-
bases from ConsensusPathDB.
DISCUSSION
The current data sets though limited have provided valuable pre-
liminary data pertaining to the etiology of steatosis and have
provided the foundation for a more extended analysis based on an
extensive collection of liver biopsies, serum, and dermal fibroblast
from patients with distinct grades of disease progression.
The transcriptome, proteome, and modeling data obtained
from fibroblasts derived from patients with steatosis (H0007,
H0008) and control (H0002) has unveiled the following novel
results.
The ribosomal protein PRAS40, abundant in steatosis patients
has been identified as a crucial regulator of insulin signaling and
also as mediator of AKT signals to mTOR (Vander Haar et al.,
2007). Furthermore, it has been shown that PRAS40 phospho-
rylation is decreased under insulin-resistant conditions (Nasci-
mento et al., 2006). Therefore, reduced AKT/mTOR signaling of
skin fibroblasts derived from steatosis patients has revealed that
the insulin-resistant phenotype is present not only in insulin-
metabolizing central organs, e.g., the liver of steatosis patients, but
is also manifested in skin fibroblasts derived from these patients.
Our results imply a down-regulation of mTOR under insulin-
resistant conditions. However, different correlations between
mTOR activity and insulin resistance in animal models (Wang
et al., 2010; Medeiros et al., 2011) and humans (Ost et al., 2010;
Pereira et al., 2012) is still a matter of an ongoing discussion. In
several studies on animals with insulin resistance induced by high-
fat diet, activation of mTOR has been observed (Um et al., 2004,
2006; Khamzina et al., 2005).
Network analysis of expression data of steatosis samples vs.
control employing tools such as DAVID, ConsensusPathDB, and
IMPaLA has revealed several pathways and functional modules of
the disease like glutathione metabolism. Based on these pathways
and modules a first model prototype of steatosis related processes
has been developed employing the modeling and simulation sys-
tem PyBioS3 (Wierling et al., 2007). PyBioS has an integrated
interface to the ConsensusPathDB facilitating the semi-automatic
development of annotated models integrating signaling pathways,
metabolic reactions and gene-regulatory processes.
The model prototype which is implemented in PyBioS (see text
footnote 3) is based on a minimal network comprising a regu-
latory network based on the transcription factor SREBF1, linked
to a metabolic network of glycerolipid and fatty acid biosynthe-
sis including the downstream transcriptional targets of SREBF1,
LIPIN1 (LPIN), and LDLR (Figure 11). The increased expression
of LPIN1 in patients with steatosis, together with the fatty acid-
induced translocation of LPIN1 to the endoplasmic reticulum,
3http://pybios.molgen.mpg.de
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FIGURE 10 |The user interface of the livSYSiPS data management
system provides clear and easy-to-use access to project related
data via the central search box and direct links to relevant data
categories, e.g., the KEGG link on the left navigation bar
addressing pathway analysis results of experimental data. Shown
here are search results for experimental data of steatosis patients
focusing on the gene ACSL3 (long-chain acyl-CoA synthetase) which
plays an important role in the fatty acid metabolism pathway. Search
results link to follow-up representations and visualizations of models
and data.
facilitates increased triacylglycerol synthesis. In addition, Ide et al.
(2004) reported a link between SREBF1 and insulin signaling as
SREBF1 is shown to directly repress the transcription of IRS-2 and
inhibit hepatic insulin signaling.
For subsequent model analysis we will employ a Monte Carlo-
based simulation strategy, in which the kinetic parameters are
repeatedly sampled from specific probability distributions and
used for multiple parallel simulations (Wierling et al., 2012). This
facilitates the analysis of large networks of signal transduction,
metabolic and gene-regulatory processes, integrating diverse
omics data for model refinement, and validation.
We aimed as well to generate a metabolic model of steatotic
phenotype. Interestingly among the pathways enriched in steato-
sis vs. control was the glutathione pathway. Subsequently our
investigation involved the mapping of mRNA expression data to a
kinetic model of the glutathione synthesis pathway. Adopting this
pathway-oriented approach we focused on a subset of complete
pathways, rather than all genes of the genome. We have extended
www.frontiersin.org September 2012 | Volume 3 | Article 339 | 13
Jozefczuk et al. iPSCs-based model of steatosis
FIGURE 11 | Visualization of a minimal model of processes found to be
related to steatosis based on our data, implemented in the modeling
and simulation system PyBioS. Differentially expressed genes
(limmapa<0.05) of the steatosis patients H0007 and H0008 vs. control
H0002 are highlighted by red frames. Two major components of the model
that have been identified by expression analysis are the transcription factor
sterol regulatory element binding protein 1 (SREBF1) and the peroxisome
(Continued)
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FIGURE 11 | Continued
proliferator-activated receptor gamma (PPARG). Furthermore, the network
integrates important components related to fatty acid synthesis, like fatty
acid synthase (FASN ) and sterol-CoA desaturase (SCD), as well as key
components of glycerolipid biosynthesis, like LIPIN1 and LDLR (both are
regulated by SREBF1). Details of the differentially regulated components
are depicted in the table (column headers from left to right: “name”: gene
probe name; “meant,” “meanc”: mean treatment values in
treatment/steatosis patients and non-steatosis, respectively; “stderrt,”
“stderrc”: SE for treatment and control; “ratio,” quotient of
meant/meantc; “log2ratio,” log-2 ratio; “limmapa,” q-value based on the
statistics of the limma-package).
this approach to fatty acid biosynthesis, fatty acid metabolism, bile
acid pathway, gluconeogenesis, urea cycle, glycolysis, tricarboxylic
acid cycle, and glyoxalate shunt; all of which have vital roles in
regulation, and are either directly or indirectly involved in the
successful functioning of the liver.
Upon data acquisition from all patient-specific samples, var-
ious cellular networks will be perturbed by changing environ-
mental conditions of iPS-derived, diseased and healthy cells.
The impact of the perturbation will be assessed by construct-
ing key networks from the most significantly dysregulated genes
to evaluate any changes as measured and the consequences of
these changes as they present themselves throughout the cellular
networks.
Ultimately hepatocyte-like cells derived from patient-specific
iPS cells will be challenged by free fatty acid overload and high
glucose which resemble environmental conditions during the pro-
gression of steatosis. Moreover this in vitro model will also lay
the foundation for identifying drug targets that may be used for
treatment of steatosis. Subsequently, hepatocyte-like cells derived
from healthy and diseased individuals would allow us to demon-
strate the differences in response to clinically relevant drugs and
enable to predict hepatotoxicity. We anticipate that the knowledge
gained from this minimal number of patient samples will prove
advantageous and beneficial to our ongoing analysis with a larger
sample of steatosis patients and healthy controls. Undoubtedly, the
application of high-throughput transcriptomics, metabolomics
proteomic, and modeling to study healthy and stressed liver,
will broaden our meager knowledge of steatosis thus, providing
deeper insights into the mechanisms underlying the progression
to steatohepatitis.
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APPENDIX
Table A1 |The range ofVmax inputted into the model for the control model (H0002), patient H0007, and H0008.
GSH
model
values
Patient
H0008
low
Patient
H0008
high
Patient
H0007
low
Patient
H0007
high
Control
H0002
low
Control
H0002
high
S-Adenosylhomocysteine hydrolase Vmfah 1500.00 2005.01 2088.17 1106.75 1236.85 1478.93 1521.07
Betaine-homocysteine methyltransferase Vmbhmt 24680.00 22348.57 29391.36 22135.64 34694.13 22504.66 26855.34
Cystathionase Vmcbs 464400.00 783199.77 783199.77 347083.33 456403.00 446706.26 482093.74
4-Nitrophenol-2-monooxygenase VmP450E1 554.50 488.81 715.53 401.15 899.06 547.34 570.43
DNA-methyltransferase Vmmeth 1500.00 1127.28 1276.94 607.06 675.93 1422.52 1577.48
Glutamylcysteine synthetase vGCLf1 2527.00 3590.25 3644.53 2235.68 2371.17 2502.93 2551.07
Gamma-glutamylcyclotransferase vGCTA 55982.80 78150.56 91180.97 38799.69 55403.46 54293.30 57672.30
Gamma-glutamyltranspeptidase vGGT 8745.00 8833.35 9624.77 7820.17 9150.53 7634.06 9855.94
Glycine N -methyltransferase Vmmet 597.90 613.03 613.28 548.21 558.17 552.76 643.04
Glutathione peroxidase vmGPX 188.50 197.74 279.53 153.70 296.32 174.69 202.31
Glutathione reductase vmgr 28.71 24.19 38.77 23.52 26.78 28.58 28.84
Glutathione synthetase vGSf1 1548.00 1944.51 1971.09 1252.10 1327.90 1325.19 1770.81
Methionine-adenosyl transferase I vmMATI 1000.00 937.95 1294.94 978.14 1116.75 989.36 1004.43
Methionine synthase (MS) vmMS 309.70 333.69 384.73 217.11 233.46 293.39 326.01
5-Oxoprolinase vop 858301.00 784837.61 1680453.16 749856.81 1318690.96 737257.83 979344.17
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